Insurance Denied Weight Loss Medication (Ozempic, Wegovy, Mounjaro): How to Appeal

GLP-1 receptor agonists — including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — represent a genuine breakthrough in obesity treatment. Clinical trials show 15–25% body weight reduction, with significant improvements in cardiovascular outcomes, diabetes control, and metabolic health. Despite this evidence, insurance denials for these medications remain extremely common, typically citing plan exclusions, BMI thresholds not met, or step therapy requirements. Here is how to appeal effectively.

Why Insurers Deny Weight Loss Medications

Formulary exclusion or "weight loss drugs not covered." Many employer self-funded plans exclude weight management medications as a category, even though GLP-1 drugs have FDA-approved indications beyond obesity. This is the most common denial for Wegovy and Zepbound, which are approved specifically for chronic weight management.

"Not FDA-approved for weight loss" argument. Ozempic (semaglutide) is FDA-approved for type 2 diabetes — not specifically for weight loss (Wegovy is). Mounjaro is FDA-approved for diabetes; Zepbound for weight management. If your prescription was for Ozempic or Mounjaro and the denial cites off-label use for weight loss, the correct counter-argument is to cite the diabetic indication if applicable, or argue that off-label prescribing for medically indicated obesity treatment is supported by clinical evidence.

BMI threshold not met. Wegovy's FDA approval criteria: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, or sleep apnea). If your BMI is near the threshold or the comorbidity documentation is insufficient, the insurer may deny.

Step therapy — prior weight loss treatment failure required. Many plans require documented failure of a formal supervised weight loss program, dietary counseling, or an older anti-obesity medication (orlistat, phentermine/topiramate) before approving GLP-1 medications.

Cardiovascular indication not invoked. The SELECT trial (2023) demonstrated that semaglutide (Wegovy) reduces major adverse cardiovascular events by 20% in adults with cardiovascular disease and overweight/obesity who do not have diabetes. The FDA approved the cardiovascular risk reduction indication in March 2024. If your insurer is denying Wegovy for weight management but you have established cardiovascular disease, the cardiovascular indication may provide a separate coverage argument.

Common denial codes: CO-96 (non-covered charge — benefit exclusion), CO-50 (not medically necessary), CO-197 (Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization required), CO-119 (benefit maximum reached).

What Clinical Guidelines Say

American Diabetes Association (ADA) Standards of Care (2024): Recommends GLP-1 receptor agonists as first-line or early medication for patients with type 2 diabetes, particularly those with established ASCVD, heart failure, or CKD. For patients with obesity and diabetes, these medications address both conditions simultaneously.

American Gastroenterological Association (AGA) Clinical Practice Update (2022): Recommends GLP-1 agonists as an evidence-based treatment option for obesity management when BMI criteria are met.

American Heart Association/American College of Cardiology (AHA/ACC): Following the SELECT trial, the ACC/AHA 2023 obesity and cardiovascular risk statement recognizes GLP-1 medications as part of comprehensive cardiovascular risk reduction.

Obesity Medicine Association (OMA) and the Endocrine Society both support pharmacological treatment of obesity as a medically necessary intervention for chronic disease management.

FDA approvals:

• Wegovy (semaglutide 2.4 mg): Approved June 2021 for chronic weight management; additional MACE risk reduction approval March 2024
• Zepbound (tirzepatide): Approved November 2023 for chronic weight management
• Ozempic (semaglutide 1 mg, 2 mg): Approved for type 2 diabetes
• Mounjaro (tirzepatide): Approved for type 2 diabetes

Step-by-Step Appeal Strategy

Step 1: Identify the specific denial reason. Is it a formulary exclusion, a BMI/criteria dispute, a step therapy requirement, or a coding issue? Each requires a different approach.

Step 2: For formulary exclusions, request a medical necessity exception. Your physician should submit a formulary exception request stating that:

• The patient has BMI ≥30 (or ≥27 with documented comorbidities)
• The specific comorbidities are listed with ICD-10 codes and clinical documentation
• Why the prescribed medication is medically necessary for this patient's chronic disease management
• What lower-cost alternatives have been tried and why they are inadequate

Step 3: Invoke cardiovascular indication if applicable. If you have established cardiovascular disease (atherosclerotic CVD, prior MI, prior stroke), and are overweight or obese, cite the FDA's March 2024 MACE reduction approval for Wegovy and the SELECT trial results (N Engl J Med 2023). This creates a separate, non-obesity medical necessity argument.

Step 4: Address step therapy with documentation. If the plan requires prior failure of another treatment, document what was tried: dietary counseling records, registered dietitian visits, commercial weight loss program participation (Weight Watchers, OPTIFAST), prior anti-obesity medications tried and outcomes.

Step 5: Document comorbidities comprehensively. For BMI 27–29.9 cases, the comorbidity documentation is everything. Include:

• HbA1c for diabetes (ICD-10 E11.x)
• Blood pressure readings and antihypertensive medications for hypertension (I10)
• AHI from sleep study for sleep apnea (G47.33)
• Lipid panel for dyslipidemia (E78.x)

Step 6: Request External Independent Review: Complete Guide" class="auto-link">external review. External reviewers applying ADA and OMA guidelines frequently overturn denials that conflict with current evidence-based obesity treatment recommendations.

Documentation Checklist

• Denial letter with reason code and formulary/coverage policy cited
• BMI documentation from clinic records (height/weight measurements over time)
• Comorbidity documentation with objective measures (lab values, blood pressures, AHI)
• Prescribing physician's letter of medical necessity
• FDA approval summary for the specific drug prescribed
• ADA Standards of Care reference (for diabetes indication)
• SELECT trial reference for cardiovascular indication (if applicable)
• Prior treatment history (dietary counseling, prior medications, commercial programs)
• Prior authorization request and denial

Fight Back With ClaimBack

GLP-1 medication denials are among the fastest-growing insurance disputes as these drugs become standard of care for obesity and diabetes management. Whether your insurer excluded the drug categorically or disputed BMI criteria, ClaimBack helps you build an appeal with the clinical evidence and FDA approval data that wins. ClaimBack generates a professional appeal letter in 3 minutes.

Start your free claim analysis →

Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal